Litigation Details for Dexcel Pharma Technologies Ltd. v. Apotex Corp. (N.D. Ill. 2018)
✉ Email this page to a colleague
Dexcel Pharma Technologies Ltd. v. Apotex Corp. (N.D. Ill. 2018)
| Docket | ⤷ Try a Trial | Date Filed | 2018-07-30 |
| Court | District Court, N.D. Illinois | Date Terminated | 2018-10-31 |
| Cause | 28:1331 Federal Question | Assigned To | Ronald A. Guzman |
| Jury Demand | None | Referred To | |
| Patents | 9,023,391 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Dexcel Pharma Technologies Ltd. v. Apotex Corp.
The small molecule drug covered by the patent cited in this case is ⤷ Try a Trial .
Details for Dexcel Pharma Technologies Ltd. v. Apotex Corp. (N.D. Ill. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-07-30 | 3 | memorandum in support of motion | infringed two Dexcel-owned patents, i.e., U.S. Patents 9,023,391 (“the ’391 Patent,” granted May 5, 2015) … the patents-in-issue during the time she worked as a patent agent, and prosecuted these patents for Dexcel…relating to the patents-in-suit, as Dexcel’s U.S. patent agent, fall squarely within this patent-agent privilege…,255,878 (“the ’878 Patent,” granted August l4, 2007), collectively, the “patents-in-suit”. The action…Graeser”) is a U.S. patent agent, and has been registered to practice before the U.S. Patent and Trademark | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
